New treatment options in the management of glioblastoma multiforme: a focus on bevacizumab

Argirios Moustakas
Teri N Kreisl
National Cancer Institute, Neuro-Oncology Branch, National Institutes of Health, Bethesda, Maryland, USA

Abstract: Glioblastoma multiforme (GBM) is the most common malignant primary brain tumor in adults and carries the poorest prognosis. Despite recent progress in molecular biology, neuro-imaging and neuro-surgical care, the management of patients with GBM continues to harbor significant challenges. Survival after diagnosis is poor even with the most aggressive approach using multimodality therapy. Although the etiology of malignant gliomas is not known, the dependency of tumor growth on angiogenesis has identified this pathway as a promising therapeutic target. Bevacizumab was the first antiangiogenic therapy approved for use in cancer and received accelerated Food and Drug Administration approval for the treatment of recurrent GBM in 2009, the first new drug for this disease in over a decade. This review describes the rationale behind the treatment of GBM with bevacizumab. The pharmacology, efficacy, safety and tolerability of bevacizumab will also be reviewed.

Keywords: glioblastoma multiforme, angiogenesis, bevacizumab

Introduction
Cancers of the brain and nervous system are relatively rare. Glioblastoma multiforme (GBM) continues to be the most common and lethal malignant primary brain tumor in adults.1 The exact pathogenesis thus far has remained elusive, and most occur in a sporadic fashion.2–5 Rarely they occur in the setting of hereditary syndromes.6 Despite an aggressive multimodal approach, the median survival time after diagnosis is approximately a year with population-based studies demonstrating even lower median survival rates.9,10 Surgery allows histological diagnosis and can provide relief for neurological deficits related to mass effect. Surgery, however, is not curative due to the infiltrative nature of the disease. While only retrospective data are available to evaluate survival benefit, extent of resection correlates with better prognosis.11–13 Radiation therapy has been the mainstay treatment for GBM for decades extending median survival to about 9 months versus a median survival of 3 months with no therapy.14–18 The role of chemotherapy in gliomas has historically been disappointing, with adjuvant therapy extending longer-term survival in the minority of GBM patients.16,17,19 This is in contrast to the more chemosensitive oligodendrogliomas harboring 1p/19q deletions.20 Chemotherapy as standard of care for GBM was only recently established in 2005, when Stupp et al demonstrated that daily temozolomide (TMZ) combined with radiation followed by 6 months of adjuvant monthly cycle TMZ increased median survival by 3 months when compared to radiotherapy alone, and increased 2-year survival from 10% to 26%.21 Once disease progression occurs, available salvage chemotherapies are usually unsuccessful, demonstrating a 6-month progression-free survival (PFS-6) of only 15%.22
Because of its poor prognosis with current multimodality treatment, a concerted effort is underway to develop new and novel therapeutic strategies that will increase survival and quality of life in patients with GBM. There has been progress in elucidating the molecular changes that underlie the pathogenesis of GBM. GBMs are hypervascular in nature and growth has been shown to be angiogenesis-dependent. Bevacizumab is a humanized monoclonal antibody against vascular endothelial growth factor (VEGF) and has been shown to be an extremely potent inhibitor of angiogenesis. Based on an improved response rate compared to that of historical controls, bevacizumab (Avastin®; Genentech, San Francisco, CA, USA) received accelerated approval by the Food and Drug Administration (FDA) for recurrent GBM in May 2009, thereby becoming the first new drug labeled for gliomas in over a decade. We will review the role of VEGF pathways in glioma angiogenesis and the rationale for bevacizumab in this disease.

**Angiogenesis in brain tumors**

For tumors to attain a size beyond a few millimeters requires a process known as angiogenesis. Angiogenesis is a physiological process that depends on a well orchestrated balance of angiogenic factors and inhibitors that control the growth of microvessel sprouts via migration and proliferation of endothelial cells. When dysregulation of this process occurs, it may provide a suitable milieu for the initiation and maintenance of certain chronic disease states such as psoriasis, ocular neovascularization and atherosclerosis. In addition, pathological angiogenesis has been shown to be a hallmark of certain tumor types such as GBM, colorectal carcinoma, breast and renal cell carcinomas. Tumor-associated neo-vascularization differs from physiological angiogenesis, characterized by a substantial increase in the proliferation activity of endothelial cells that are structurally “leaky”. Tipping the scales in favor of a proangiogenic state requires upregulation of factors such as VEGF-A, platelet-derived growth factor (PDGF) and basic fibroblast growth factor (bFGF2). Additional pathways implicated in tumor angiogenesis are angiopoietin and Notch. Enzymes such as metalloproteinase and serine proteinase have also been identified as possible substrates for therapeutic intervention.

Tissue hypoxia resulting from a tumor’s fast exponential growth has been a well-defined trigger of angiogenesis in solid tumors and manifests downstream by a number of inducible proangiogenic molecular changes. One such example involves hypoxia-inducible factor-1, a transcription factor that regulates the expression of many angiogenesis- and glucose metabolism-related genes and in addition activates the transcription of VEGF in malignant gliomas. VEGF mRNA expression, as well as VEGF receptor expression, are well documented hypoxic induced changes in malignant gliomas.

Various chemokines and mitogens that promote angiogenesis have been shown to be produced by both primary and recurrent gliomas and include basic fibroblast growth factor, interleukin-8 (CXCL8), CXCL12, and hepatocyte growth factor/scatter factor. Neurotrophins and their corresponding receptors, which primarily mediate their effects via the receptor kinases TrkA-C, have been shown to support endothelial cell survival and proliferation as well as neuronal proliferation, differentiation and synaptogenesis. Other mechanisms include endothelial-cell spread and migration in response to certain growth factors mediated by certain integrins, as well as signaling via stem cell factor and its receptor c-Kit pathway, which is thought to be central in inducing tumor-based angiogenesis.

**VEGF-mediated angiogenesis**

The first observations of the increased vascular nature of brain tumors were made by Rudolf Virchow during the nineteenth century. Later, based upon the concept that tumor angiogenesis was mediated by diffusible factors produced by tumor cells, Folkman proposed that inhibition of angiogenesis would be a reasonable strategy to treat cancer and initiated the isolation of tumor angiogenesis factors. In 1983, Senger et al reported the partial purification of vascular permeability factor (VPF), a protein that induced vascular leakage in the skin. In 1989, Ferrara et al isolated VEGF, an endothelial-cell-specific mitogen. The proteins VEGF and VPF were shown to be one and the same molecule by the work of Connolly et al. VEGF and its signaling are important mediators of glioma-induced angiogenesis.

The human VEGF gene has been located to chromosome 6p21.3. VEGF has been described as a basic, heparin-binding, homodimeric glycoprotein. There are at least five VEGF glycoproteins (VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E) and placental growth-factors PIGF-1 and PIGF-2 that belong within the same family. VEGF-A binding is the dominant mediator of pro-angiogenic signaling in human cancers and VEGF-A has different isoforms that are generated by alternate splicing. The VEGF glycoprotein...
acts in a number of ways to mediate the above-described effects. It binds two related receptor tyrosine kinases (RTK), named Flt-1 (VEGFR-1) and KDR/Flk-1 (VEGFR-2) and interacts with a family of co-receptors known as neuropilins. By binding to these receptors, VEGF (and in a similar manner PDGF), induces homodimerization of two receptor subunits and thereby induces autophosphorylation of the intracellular tyrosine kinase domains. This phenomenon then leads to downstream signal transduction. VEGFR-3 has been shown to mediate the mitogenic and survival activity of VEGF via the phosphatidylinositol-3 kinase/phosphatase and tensin homologue/Akt/mammalian target of rapamycin (PtdIns3K/Akt/mTOR) pathway, the PLCγ and Ras/Raf/mitogen-activated protein kinases MAPK p44/42.

The Notch transmembrane protein and its ligand Jagged/Delta are activated by VEGF signaling and tend to suppress angiogenesis. Blocking the Delta-like ligand 4 has been shown to increase sprouting in a glioma model, paradoxically minimizing tumor growth. Notch signaling seems essential to the negative feedback control of VEGF signaling in brain tumors. In recent years another molecule known as γ-secretase, a presenilin-dependant protease complex also implicated in the pathogenesis of Alzheimer’s disease, has been identified as a significant player in the induction and maintenance of tumor-based angiogenesis by cleaving the Notch molecule. VEGFR1 and insulin-like growth factor-1, which are receptors involved in promoting angiogenesis in GBM, have also been shown to be cleaved by γ-secretase.

VEGF has been shown to be a significant regulator of embryonal and physiological and pathological angiogenesis, including that of tumor growth. In vitro studies have shown that VEGF can promote the growth of vascular endothelial cells derived from both blood vessels and lymphatic vessels, act as a survival factor for endothelial cells, induce vasodilatation, promote inflammation through vascular leakage, induce chemotaxis of endothelial cells, increase proteolytic enzyme expression and hence promote extracellular matrix degradation, promote monocyte activation and chemotaxis, and inhibit the maturation of antigen-presenting dendritic cells. A number of studies have shown that in addition to endothelial cells VEGF exerts a mitogenic and survival effect on nonendothelial cell types such as nerve cells.

The efficacy of antiangiogenic agents has been demonstrated in preclinical xenograft brain tumor models. Calabrese et al demonstrated that self-renewal capacity of brain tumor cells were maintained by endothelial factors and modulation of this “vascular niche” with antiangiogenic agents decreased tumor growth. Because VEGF plays such a significant role in the process of angiogenesis, development of therapeutic interventions targeting VEGF and VEGFR signaling is rational. The use of such agents to treat brain tumors has been increasing and to date there are a number of clinical trials in progress dedicated to this approach, including, the identification of agents that bind specifically to VEGF ligands and those that directly target VEGF receptors.

**Bevacizumab**

Bevacizumab is a recombinant humanized IgG1 monoclonal antibody (MAb) with an approximate molecular weight of 149 kD. It consists of approximately 93% human and 7% murine sequences. The antibody itself contains a human IgG1 framework region and the antigen–binding complementarity-determining regions of a murine antibody that binds to VEGF, Mab A.4.6.1. It selectively binds with high affinity (kd = 1.1 nM) and sterically inhibits all biologically active isoforms of human vascular endothelial growth factor to its receptors Flt-1 (VEGFR-1) and KDR (VEGFR-2) on the surface of endothelial cells. By activating these receptors downstream effects include tyrosine phosphorylation and induction of signal transduction pathways involved in mitogenesis and pro-survival activity within vascular endothelial cells.

**Nonhuman safety and toxicology profile**

To date there have been no studies assessing carcinogenicity or mutagenicity of bevacizumab. No studies have been conducted to investigate excretion in milk of lactating animals but excretion of IgGs is expected to occur in breast milk. In nonclinical studies using Cynomolgus monkeys it was shown that bevacizumab may impair fertility and that this may be a reversible effect once it has been stopped. In addition, when administered at doses of 0.4 to 20 times the weekly human exposure, anatomical pathology revealed several adverse effects on general growth and skeletal development, fertility and wound healing capacity. In rabbits that were treated with bevacizumab there was reduced wound healing capacity. Teratogenicity studies performed on pregnant rabbits demonstrated reduced or irregular ossification in the skull, jaw, spine, ribs, tibia and bones of the paws; meningocele; fontanel, rib and hindlimb deformities; corneal opacity; and absent hindlimb phalanges.

**Pharmacokinetic profile of bevacizumab**

The pharmacokinetic profile of bevacizumab was assessed in humans using an assay that measures total serum bevacizumab concentrations. Patients who received 1 to 20 mg/kg of
bevacizumab weekly, every 2 weeks, or every 3 weeks, had an estimated half-life of bevacizumab of 20 days, with a range of 11 to 50 days and a predicted time to reach steady state of 100 days. The clearance rate of bevacizumab was influenced by body weight, gender and tumor burden. After correcting for body weight, males had a higher bevacizumab clearance (0.262 L/day vs 0.207 L/day) and a larger Vc (3.25 L vs 2.66 L) than females.84

Human safety profile
In the initial clinical studies that led to the FDA approval of bevacizumab in colon, breast, kidney and lung cancers the short-term toxicity of bevacizumab, alone or in combination with chemotherapy, was found to be acceptable.85-90 Mild hypertension, manageable by medication, was the most common adverse event in addition to fatigue. A low frequency of more serious adverse events did occur, which included arterial thromboembolic events, congestive heart failure, bone marrow suppression, intracranial hemorrhage, impaired wound healing and gastrointestinal perforations. Toxicities may be potentiated by combining chemotherapeutic agents with bevacizumab; examples of such adverse events include anemia or fatigue, marrow suppression, neuropathy and liver dysfunction. One relatively uncommon adverse event potentiated by such a regimen is the increased risk of congestive heart failure from 0.5% to 2.2% in patients who have received prior or concomitant antracyclines. As has been demonstrated in rabbit models bevacizumab impairs wound healing. In a controlled clinical trial in patients with metastatic colorectal carcinoma who underwent surgery, the incidence of wound healing complications, including serious and fatal complications during the course of bevacizumab treatment was 15% and in those who did not receive bevacizumab, was 4%.87,88,89 In the clinical trial setting, bevacizumab was administered until at least 28 days after surgery. The appropriate timing of when bevacizumab should be discontinued during the peri-surgical period has not been determined but should take into account the half-life of the drug which is about 21 days with a range of 11 to 50 days. Although there is a potential for immunogenicity no anti-bevacizumab antibodies have been detected thus far.

Bevacizumab and non-CNS solid tumors
Bevacizumab was the first anti-angiogenic inhibitor approved as an anti-tumor therapeutic agent. On February 26, 2004, the FDA approved bevacizumab as first-line treatment for patients with metastatic colorectal cancer. In a randomized-double, blind-clinical trial of more than 800 patients with metastatic colorectal carcinoma, bevacizumab was compared to the standard chemotherapy of irinotecan, leucovorin (folinic acid) and fluorouracil (IFL). Patients who were given bevacizumab in combination with IFL survived about five months longer and the average time to tumor progression was four months longer than patients receiving IFL alone. The overall response rate to the treatment was 45% compared to 35% for the control arm of the trial.88,89 In June 2006, bevacizumab was granted labeling extension for co-administration with 5-fluorouracil-based chemotherapy for the treatment of metastatic colorectal carcinoma based on data from the E3200 trial. This trial was an open-label, randomized, three-arm, active-controlled, multi-center clinical trial in which bevacizumab alone was compared to bevacizumab plus FOLFOX4 (5-fluorouracil, leucovorin, and oxaliplatin) and FOLFOX4 alone. There was a statistically significant improvement in overall survival (OS) in patients receiving bevacizumab plus FOLFOX4 compared to those receiving FOLFOX4 alone.87

Bevacizumab received FDA approval in October of 2006 for a labeling extension for patients with unresectable, locally advanced, recurrent or metastatic nonsquamous, nonsmall cell lung carcinoma. This was based on the primary trial E4599, which was a randomized, active controlled, open label, multicenter clinical study evaluating bevacizumab plus carboplatin and paclitaxel versus carboplatin and paclitaxel alone. There was a statistically significant improvement in OS in those receiving bevacizumab with carboplatin and paclitaxel (median OS 12.3 vs 10.3 months; hazard ratio 0.80, P = 0.013 stratified log rank test).85

An accelerated approval was granted in February 2008 for use in conjunction with paclitaxel in patients with metastatic HER-2 negative breast carcinoma in a single, open-label, randomized, multi-centre study E2100. While response rates were improved there was no improvement in disease-related symptoms nor increased OS.90 To date there are no data demonstrating an improvement in disease-related symptoms or increased OS for breast cancer.

Most recently bevacizumab received FDA approval to be used in conjunction with interferon-alfa for patients with metastatic renal cell carcinoma who had undergone nephrectomy. This was largely based on data from the BO17705 trial, a randomized, double-blind, placebo-controlled, multinational clinical trial which demonstrated a median PFS of 10.2 months for the bevacizumab plus interferon arm compared to 5.4 months for the interferon and placebo arm.
Bevacizumab for glioblastoma treatment

Dovepress

Submit your manuscript | www.dovepress.com
DovePress

OncoTargets and Therapy 2010:3

31

of 13 patients with recurrent heavily pretreated malignant glioma treated with the combination of bevacizumab and irinotecan. Of the thirteen patients nine were started on bevacizumab at a dose of 5 mg/m² every 2 weeks while the rest received a dose of 10 mg/m²; irinotecan was given at a dose of 125 mg/m² every week for 3 weeks. Of the 13 treated patients, 10 (77%) had a radiographic partial response and 3 (23%) had stable disease. The median time to disease progression was 24 weeks while the mOS was 27 weeks.91 Narayana et al reported on 61 patients with recurrent high-grade gliomas treated with bevacizumab at 10 mg/kg every 2 weeks for 4 doses in an 8-week cycle along with either irinotecan or carboplatin. At a median follow-up of 7.5 months (range 1 to 19 months), 50 (82%) patients relapsed and 42 patients (70%) died of the disease. The mPFS and OS were 5 (95% CI 2.3 to 7.7) and 9 (95% CI 7.6 to 10.4) months, respectively. Radiographic responses were noted in 73.6% of cases.92 Norden et al in a retrospective study reviewed 55 consecutive

**Table 1** Selected trials of bevacizumab treatment in recurrent malignant glioma

| Study            | Patients | Regimen                                                                 | Response rate | mPFS | PFS-6 | mOS   |
|------------------|----------|------------------------------------------------------------------------|---------------|------|-------|-------|
| Ali et al91      | 13 MG    | (9) *B 5 mg/m² q2 wks (4) B 1 mg/m² + l 125 mg/m² q3 wks               | 10 (77%)      | mTTP 24 wks | 27 wks |
| Friedman et al92 | 167 GBM  | (85) *B (82) B + I                                                   | 28.2%         | 42.6% | 9.2 m |
| Kang et al93     | 27 MG    | *B + I                                                               | 37.8%         | 5.1 m  | 46%   | 12.6 m|
| Kreisl et al94   | 48 GBM   | *B 10 mg/kg q2 wks                                                   | 17 (35%)      | 16 wks (12–26) | 29% (18–48) | 31 wks (21–54) |
| Mohile et al95   | 10 GBM   | *B 10 mg/kg q2 wks + IMRT 6 Gy x5                                     | 7 (58%)       |       |       |       |
| Narayana et al96 | 37 GBM   | *B 10 mg/kg q2 wks + l 125 mg/m² q2 wks or carboplatin AUC6 q4 wks    | 39/54 (72%)   | 5 m (2.3–7.7) |       | 9 m (7.6–10.4) |
| Nghiemphu et al96| 44 GBM   | *B 5 mg/kg q2 wks + various                                        | 4.25 m        | 41%   | 9.0 m |
| Norden et al97   | 33 GBM   | *B 10 mg/kg q2 wks + various                                        | 34.1%         | 23.9 wks (17.7–28.3) | 42% GBM | 35.7 wks (27.7–61.4) |
| Poulson et al98  | 27 GBM   | *B 10 mg/kg + l q2 wks                                             | 30% GBM       | 22 wks | 40% GBM | 28 wks GBM |
| Poulson et al99  | 27 GBM   | *B 10 mg/kg + l q2 wks                                             | 15% AG        |       | 33% AG | 32 wks AG |
| Vrendenburgh et al100 | 35 GBM | (23) *B 10 mg/kg + l q2 wks (12) B 15 mg/kg q3 wks + l qwk 4/6 wks | 20 (57% (39–74)) | 24% (18–36) | 46% (32–66) | 42% (35–60) |
| Zuniga et al101  | 37 GBM   | *B 10 mg/kg + l                                                       | 25/37 (68%) GBM | 7.6 m GBM | 63.7% GBM | 11.5 m GBM NA AG |
|                  | 14 AG    | *B 10 mg/kg + l                                                       | 11/14 (79%) AG | 13.4 m AG | 78.6% AG |       |

*Number of patients.

**Abbreviations:** AG, anaplastic gliomas; B, bevacizumab 10 mg/kg every 2 weeks; B + I, irinotecan 125–340 mg/m² every 2 weeks; GBM, glioblastoma multiforme; IMRT, intensity modulated radiation therapy; MG, malignant glioma; mTTP, median time to tumor progression; m, months; NA, not available; PFS-6, 6-month progression-free survival; mOS, median overall survival; mPFS, median progression-free survival.
patients with recurrent malignant gliomas who were treated with bevacizumab and chemotherapy (irinotecan, carboplatin, carmustine, temozolomide) to determine efficacy, toxicity, and patterns of recurrence. Only 2.3% of patients had a complete response, 31.8% had a partial response, 29.5% a minimal response, and 29.5% had stable disease. A PFS-6 was 42% for patients with GBM and 32% for patients with anaplastic glioma. In a retrospective study by Zuniga et al. of bevacizumab plus irinotecan in recurrent GBM, 6 (11.8%) of 51 patients discontinued treatment due to a treatment-emergent adverse event, including one with end-stage renal failure and another with gastric perforation.

There are several prospective trials of bevacizumab in recurrent GBM patients. The first study was published by Vredenburg et al. They reported on a phase II trial of 35 patients divided into two treatment cohorts. The first cohort included 23 patients who received bevacizumab at 10 mg/kg plus irinotecan every 2 weeks. The second cohort included 12 patients who were treated with bevacizumab 15 mg/kg every 21 days and irinotecan on days 1, 8, 22, and 29. The group reported 57% of patients achieving a partial response to therapy and a PFS-6 of 46% (95% CI 32% to 66%). However, 11/35 (31%) patients discontinued therapy due to toxicity and an additional four withdrew due to fatigue. The results were an improvement when compared to historical controls which demonstrate a 6 month PFS of only 9% and response rates of 7% to 9%.

Two pivotal trials have documented the bevacizumab monotherapy experience. This included the industry-sponsored AVF3708g open-label, multi-center trial and a separate independent study, NCI 06-C-0064E, conducted at the National Cancer Institute. The AVF3708g open-label trial included a sample of 167 patients who were randomly assigned to receive bevacizumab alone or in combination with irinotecan 340 mg/m² or 125 mg/m² depending on the use of enzyme-inducing anti-seizure medications. The estimated PFS-6 rates were 42.6% (97.5% CI 29.6% to 55%) for the monotherapy group and 50.3% (97.5% CI 36.8% to 63.9%) for the combined group. While the study was not designed to be comparative, there was no statistically significant difference in survival between the two arms. Objective response rates were 28.2% (97.5% CI 18.5% to 40.3%) for the monotherapy group and 37.8% (97.5% CI 26.5% to 50.8%) for the combined group. The mOS rates were 9.2 months (97.5% CI 8.2 to 10.7 months) for the monotherapy group and 8.2 months (97.5% CI 7.8 to 10.9 months) for the combined group.

In the NCI trial, patients were treated with bevacizumab 10 mg/kg every 2 weeks. Patients who progressed were offered participation in a companion study where irinotecan 125 to 340 mg/m² was immediately added to biweekly bevacizumab. None of the patients in the NCI trial who were subsequently treated with irinotecan had a response after progression on bevacizumab alone. A response rate of 35% and PFS6 29% (95% CI 18% to 48%) were documented in the first 48 of the 56 patients enrolled into this study. As a result of the data obtained in these trials, bevacizumab received an accelerated FDA approval in May 2009 as monotherapy in patients with GBM who progressed after initial treatment.

The utility of irinotecan in combination with bevacizumab has not been established. This is of little surprise since single agent irinotecan in glioma patients has shown little efficacy in previous studies. To date, no other standard therapy has proven itself to be superior to other treatments when combined with bevacizumab for the treatment of recurrent GBM. As such, various other combinations of bevacizumab have been attempted. Mohile et al reported on a small group of 12 patients who achieved a 58% response rate and a PFS-6 of 76% with fractionated focal radiotherapy on small volume tumors. In an attempt to answer the question of whether the addition of cytotoxic agents may have a synergistic effect, various groups have reviewed their experience with bevacizumab in combination with agents such as TMZ, irinotecan, carboplatin, nitrosoureas, etoposide and erlotinib. In a group of 54 patients treated with irinotecan versus 7 patients treated with carboplatin in combination with bevacizumab no significant difference in survival was documented.

Based on the NCI trial that led to the FDA approval for bevacizumab in recurrent GBM, patients overall tolerated monotherapy well. The most frequently observed severe adverse event possibly or probably related to bevacizumab in 48 treated patients was the occurrence of thromboembolic events which occurred in six patients (12.5%). One patient experienced a stroke and the other three experienced a pulmonary embolus. None of the patients experienced an intracranial hemorrhage. Hypertension was the second most frequent drug-related adverse event that was easily treated with antihypertensive medication. Six patients (12.5%) were removed from the study for drug-associated toxicity that included five thromboembolic events, and one bowel perforation. Grade 1 proteinuria was reported in one patient and Grade 3 hepatic dysfunction was reported in one patient as well. Grade 2 and 3 thrombocytopenia was observed in 1 and 2 patients respectively.

In the AVF3708G trial, 98.8 % of patients in the bevacizumab alone arm experienced adverse events with the most common being fatigue (45.2%), headache (36.9%),
hypertension (29.8%), diarrhea (21.4%) and epistaxis (19%). Adverse events took place in all patients in the irinotecan and bevacizumab arm with the most common being fatigue (75.9%), diarrhea (74.7%), nausea (67.1%) and constipation (40.5%). Grade 3 or higher treatment emergent AEs occurred in 46.4% of bevacizumab recipients and 65.8% of bevacizumab plus irinotecan recipients. Selected AEs associated with bevacizumab treatment included arterial thromboembolism (grade ≥ 3; bevacizumab, 2.4%; in the irinotecan group, 2.5%), venous thromboembolism (bevacizumab, 3.6%; combined group, 8.9%), and wound-healing complications. Two patients (2.5%) experienced grade 3 gastrointestinal perforation and one patient (1.3%) experienced serious reversible posterior leukoencephalopathy syndrome in the combined group. A grade 1 intracranial hemorrhage was noted in two patients (2.4%) who received only bevacizumab versus 3 patients in the combined group (3.8%) experiencing a grade 1, 2 and 4 respectively. AEs led to bevacizumab discontinuation for four patients (4.8%) in the bevacizumab arm and for 14 patients (17.7%) in the irinotecan group. Two patients in the bevacizumab arm died secondary to neutropenia and pulmonary embolism while one reportedly died of a seizure within the combined group.

**Newly diagnosed malignant gliomas**

A number of investigators are conducting upfront studies for newly diagnosed GBM since survival benefit data for recurrent disease with the use of bevacizumab have not been established and will not likely be an end-point in future trials for recurrent disease. Nicholas et al reported a study of bevacizumab added to adjuvant TMZ after concurrent chemoradiation. Preliminary results from 42 of 48 enrolled patients demonstrated complete radiographic responses in 5/42 (12%) patients, a partial response in 9 (21%), 13 (31%) were stable and 7 (17%) showed progressive disease.

Lai et al reported a phase II trial of 70 patients treated with focal external beam radiation (60 Gy in 30 fractions), biweekly bevacizumab 10 mg/kg and daily TMZ 75 mg/m². After a two week post-radiation interval, combination therapy with biweekly bevacizumab and monthly TMZ was given. All but 2 patients had total or partial resections. Median follow-up was 17.2 months and 50% of the group had a Kamovsky Performance Scale of 60% to 80%. Median PFS was 13 months (95% CI 11.3 to 15.9 months) and PFS-6 was 89.1% (95% CI 78.6 to 94.7 months) compared to 8.1 months (95% CI 7.0 to 11.7 months) and 64.4% (95% CI 54.5 to 72.7 months) for an internal control group. Median OS was 25 months (95% CI 16.1 to NA) compared to 21.1 months in the control group. In the treatment group, 6- and 18-month OS was 98.6% (95% CI 90.2 to 99.8 months) and 61.1% (95% CI 45.9 to 73.3 months), respectively, compared to 88.2% (95% CI 80.5 to 93 months) and 60.6% (95% CI 50.8 to 69.1 months) in the control group. Unexpected adverse events included isolated cases of retinal detachment and optic neuropathy. The most common treatment related serious adverse effects included thrombotic complications with 12 (17%) patients being diagnosed with deep vein thrombosis. Hypertension was reported in 8 (11%) patients. Four (6%) patients had wound related infections involving their craniotomy sites. Other adverse events included involvement of the gastrointestinal and renal systems. Neurological events included seizures in 5 (7%) patients, transient ischemic attack/stroke in 3 patients and 1 patient with a traumatic hemorrhage.

A similarly designed study of 15 patients was reported by Narayana et al with 1-year PFS and OS being 59.3% and 86.7% respectively. Radiographic responses were noted in 13 of 14 assessable patients (92.8%). Gruber et al utilized a more dose intense schedule of adjuvant TMZ with bevacizumab for newly diagnosed GBM. The PFS-6 survival was 77.5%, the median PFS was 17 months, while the 1- and 2-year OS was 83% and 57%, respectively.

Two ongoing randomized phase III trials will investigate the efficacy and safety of adding bevacizumab to standard upfront chemoradiation with temozolomide. A phase III, double-blind, placebo controlled trial (Radiation Therapy Oncology Group 0825) has a target accrual of 720 patients. Patients with newly diagnosed GBM will undergo 3 weeks of standard chemoradiation and in addition will undergo analysis for MGMT promoter methylation and molecular profiling. Patients will then be stratified into two arms for the final 3 weeks of chemoradiation. The first arm will receive concurrent placebo while the second arm will receive biweekly bevacizumab. This will be followed by adjuvant treatment in which the first arm will continue with placebo in addition to TMZ and the second arm will receive TMZ with biweekly bevacizumab. The other phase III trial is an industry sponsored randomized, double-blind, placebo-controlled trial with an expected target accrual of over 500 patients. In this trial patients will be randomly assigned to either bevacizumab or the placebo arm, in combination with standard radiation therapy plus temozolomide for 6 weeks. After a 4 week hiatus, patients will continue to receive bevacizumab or placebo, plus adjuvant temozolomide for 6 cycles of maintenance therapy. Bevacizumab or placebo monotherapy will then continue until disease progression.
As yet, the role of bevacizumab in the upfront management of GBM remains to be determined.

**Bevacizumab and its clinical benefit**

The effects of bevacizumab on vascular permeability are akin to the effects of steroids on cerebral edema. We, therefore, have at our disposal another drug other than dexamethasone that can produce improvement of neurological signs and symptoms, which can translate into improved quality of life. This was demonstrated in the two trials that led to the FDA approval of bevacizumab in recurrent GBM. In the NCI trial, 50% patients had decreased cerebral edema. Approximately 58% of patients on steroids at the start of treatment were able to achieve an average dose reduction of 59% and 52% had improved neurological symptoms. Findings were similar in the industry sponsored trial which also assessed cognitive function. The majority of patients demonstrated stable performance on a variety of tests at the six week follow-up and 18% to 25% had improved performance. Bevacizumab clearly has a role in the treatment of patients with GBM, independent of survival benefit, for its steroid-sparing effect.

The dramatic effects of bevacizumab on the MRI contrast signal (Figure 1) is at least partially a result of its effect on vascular permeability since reduction in enhancement can be observed with just one dose of the drug; too short of an interval for true tumorcidal activity. Consequently, MRI contrast signal may not be a reliable proxy marker for extent of tumor as it is for evaluating cytotoxic therapy. For this reason alternative imaging methods are being investigated to assess tumor response such as dynamic susceptibility contrast enhanced MRI and apparent diffusion coefficient measures.

Despite the beneficial effect of bevacizumab, concern has arisen that it may actually influence the pattern of disease progression and thereby promote tumor invasion. This was observed in both in vitro and in vivo studies which demonstrated the up-regulation of invasion related genes such as MMP 9 or other pro-angiogenic factors. The pattern of relapse, prognosis and outcome of further therapy in patients who failed bevacizumab was recently described in an institutional review. Iwamoto et al reported a series of 37 patients with recurrent GBM who progressed on treatment with bevacizumab. The mOS after progression on bevacizumab was 4.5 months. Seventeen patients (46%) had local recurrence and 6 (16%) had multifocal recurrence. Thirteen patients (35%) had non-enhancing disease progression. The patients with non-enhancing tumor did worse with shorter survival, which was thought to be due to a larger disease burden impacting negatively on performance status. Non-enhancing tumor was also thought to be an independent

---

**Figure 1.** A) Axial T1-weighted, post-contrast image of the brain in a patient with glioblastoma multiforme who progressed on temozolomide therapy. B) Response after 2 months of bevacizumab monotherapy.
prognostic factor. Similar findings were reported by Zuniga et al but others have reported lower rates of infiltrative disease on the order of 20% to 30%. It is difficult to discern whether anti-VEGF therapy actually accelerates or promotes tumor invasion or whether the natural course of the disease is altered so that patients are alive long enough for us to observe this degree of tumor progression, unmasked by the effect bevacizumab has on gadolinium enhancement. It is clear that clinical trials that are using anti-VEGF therapy will need to measure response using methods that incorporate evaluation of non-enhancing disease.

While bevacizumab appears to be an effective agent for recurrent GBM, the majority of patients do not achieve durable disease control and other salvage regimens are required. Often, adding a cytotoxic agent or switching the companion cytotoxic agent is attempted, but efficacy of this practice is unclear. Quant et al described a retrospective review of 54 patients with recurrent MG who progressed on either bevacizumab mono- or combination therapy who were then subsequently treated with an alternate bevacizumab-containing regimen. Tumor progression was determined clinically and radiographically. The median prior chemotherapy regimens including the first bevacizumab-containing regimen was 3 (range, 2 to 5). The mPFS on the first bevacizumab-containing regimen was 124 days (95% CI 87 to 154 days); PFS-6 was 33% and the mPFS on the second bevacizumab-containing regimen was 37.5 days (95% CI 34 to 42 days) with a PFS-6 of 2%. In the review by Iwamoto et al 19 of the 37 patients received salvage chemotherapy after failure with bevacizumab. The mOS in those who received salvage treatment was 5.2 months and the PFS-6 was 0%. It is clear that other therapeutic options need to be considered for such patients.

**Conclusion**

Tumor angiogenesis has emerged as a valid therapeutic target in clinical oncology and the VEGF system represents a key mediator in this process. While monotherapy with bevacizumab for recurrent GBM has afforded encouraging results, it by no means approaches a cure or durable disease control for the majority of patients. Continued efforts are needed to improve on this early success. Rational combinations of targeted therapy with bevacizumab are appropriately being studied, as well as bevacizumab’s role in the upfront treatment of glioma patients. The post-bevacizumab era will prove to be a challenging environment for the neuro-oncology community in evaluating new salvage therapy, but one that for the first time may carry real promise.

**Disclosures**

The authors disclose no potential conflicts of interest.

**References**

1. Hayat MJ, Howlader N, Reichman ME, Edwards BK. Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program. Oncolist. 2007;12(1):20–37.
2. Holick CN, Giovannucci EL, Rosner B, Stampfer MJ, Michaud DS. Prospective study of cigarette smoking and adult glioma: dosage, duration, and latency. Neuro Oncol. 2007;9(3):326–334.
3. Huncharek M, Kupelnick B, Wheeler L. Dietary cured meat and the risk of adult glioma: a meta-analysis of nine observational studies. J Environ Pathol Toxicol Oncol. 2003;22(2):129–137.
4. Karipidis KK, Benke G, Sim MR, et al. Occupational exposure to ionizing and non-ionizing radiation and risk of non-Hodgkin lymphoma. Int Arch Occup Environ Health. 2007;80(8):663–670.
5. Karipidis KK, Benke G, Sim MR, Yost M, Giles G. Occupational exposure to low frequency magnetic fields and the risk of low grade and high grade glioma. Cancer Causes Control. 2007;18(3):305–313.
6. Insipid PD, Tarone RE, Hatch EE, et al. Cellular-telephone use and brain tumors. N Engl J Med. 2001;344(2):79–86.
7. Vilchez RA, Butel JS. Emergent human pathogen simian virus 40 and its role in cancer. Clin Microbiol Rev. 2004;17(3):495–508.
8. Reuss D, von Deimling A. Hereditary tumor syndromes and gliomas. Recent Results Cancer Res. 2009;171:83–102.
9. Krex D, Klink B, Hartmann C, et al. Long-term survival with glioblastoma multiforme. Brain. 2007;130(Pt 10):2596–2606.
10. Smith JS, Jenkins RB. Genetic alterations in adult diffuse glioma: occurrence, significance, and prognostic implications. Front Biosci. 2000;5:D213–D231.
11. Lacroix M, Abi-Said D, Fourney DR, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg. 2001;95(2):190–198.
12. Hess KR. Extent of resection as a prognostic variable in the treatment of gliomas. J Neurosurg. 1999;82(3):227–231.
13. Metcalfe SE, Grant R. Biopsy versus resection for malignant glioma. Cochrane Database Syst Rev. 2001(3):CD002034.
14. Bloom HJ. Combined modality therapy for intracranial tumors. Cancer. 1975;35(1):111–120.
15. Salazar OM, Rubin P, Feldstein ML, Pizzutiello R. High dose radiation therapy in the treatment of malignant gliomas: final report. Int J Radiat Oncol Biol Phys. 1979;5(10):1733–1740.
16. Walker MD, Alexander EJ, Hunt WE, et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg. 1978;49(3):333–343.
17. Walker MD, Green SB, Byar DP, et al. Randomized comparisons of radiotherapy and nitrosourea for the treatment of malignant glioma after surgery. N Engl J Med. 1980;303(23):1323–1329.
18. Walker MD, Strike TA, Sheline GE. An analysis of dose-effect relationship in the radiotherapy of malignant gliomas. Int J Radiat Oncol Biol Phys. 1979;5(10):1725–1731.
19. Fine HA, Dear KB, Loeffler JS, Black PM, Canellos GP. Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer. 1993;71(8):2585–2597.
20. Cairncross JG, Macdonald DR. Successful chemotherapy for recurrent malignant oligodendroglioma. Ann Neurol. 1988;23(4):360–364.
21. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–996.
22. Wong ET, Hess KR, Gleason MJ, et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol. 1999;17(8):2572–2578.
23. WH L. The vascular pattern of tumors. Johns Hopkins Hosp Bull. 1927;41:156–162.
24. Folkman J. Tumor angiogenesis: therapeutic implications. *N Engl J Med*. 1971;285(21):1182–1186.

25. Folkman J. Anti-angiogenesis: new concept for therapy of solid tumors. *Ann Surg*. 1972;175(3):409–416.

26. Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. *Nat Rev Drug Discov*. 2004;3(5):391–400.

27. Sholley MM, Ferguson GP, Seibl HR, Montour JL, Wilson JD. Mechanisms of neovascularization. Vascular sprouting can occur without proliferation of endothelial cells. *Lab Invest*. 1984;54(6):624–634.

28. Folkman J. Angiogenesis in psoriasis: therapeutic implications. *J Invest Dermatol*. 1972;59(1):40–43.

29. Miller JW, Adams AP, Shima DT, et al. Vascular endothelial growth factor/vector permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model. *Am J Pathol*. 1994;145(3):574–584.

30. Moulton KS. Angiogenesis in atherosclerosis: gathering evidence beyond speculation. *Curr Opin Lipidol*. 2006;17(4):548–555.

31. Ferrara N. VEGF and the quest for tumour angiogenesis factors. *Nat Rev Cancer*. 2002;2(10):795–803.

32. Baluk P, Hashizume H, McDonald DM. Cellular abnormalities of blood vessels as targets in cancer. *Curr Opin Genet Dev*. 2005;15(1):102–111.

33. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. *Cell*. 1996;86(3):353–364.

34. Folkman J. Angiogenesis: an organizing principle for drug discovery? *Nat Rev Drug Discov*. 2007;6:273–286.

35. Folkman J. Is angiogenesis an organizing principle in biology and medicine? *J Pediatr Surg*. 2007;42(1):1–11.

36. Kerbel RS. Tumor angiogenesis. *N Engl J Med*. 2008;358(19):2039–2049.

37. Fang J, Shing Y, Wiederschain D, et al. Matrix metalloproteinase-2 is required for the switch to the angiogenic phenotype in a tumor model. *Proc Natl Acad Sci U S A*. 2000;97(8):3884–3889.

38. Maxwell PH, Dachs GU, Gleadle JM, et al. Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. *Proc Natl Acad Sci U S A*. 1997;94(15):8104–8109.

39. Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. *Nature*. 1992;359(6398):843–845.

40. Plate KH, Breier G, Weich HA, Risau W. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. *Nature*. 1992;359(6398):845–848.

41. Auguste P, Gursel DB, Lemiere S, et al. Inhibition of fibroblast growth factor/flowbblast growth factor receptor activity in glioma cells impedes tumor growth by both angiogenesis-dependent and -independent mechanisms. *Cancer Res*. 2001;61(4):1717–1726.

42. Salmaggi A, Eoh M, Frigerio S, et al. Intracavitary VEGF, hFGF, IL-8, IL-12 levels in primary and recurrent malignant glioma. *J Neurooncol*. 2003;62(3):297–303.

43. Schmidt NO, Westphal M, Hagel C, et al. Levels of vascular endothelial growth factor, heparanase growth factor/scatter factor and basic fibroblast growth factor in human gliomas and their relation to angiogenesis. *Int J Cancer*. 1999;84(1):10–18.

44. Li M, Ransohoff RM. The roles of chemokines CXCL12 in embryonic and brain tumor angiogenesis. *Semin Cancer Biol*. 2009;19(2):111–115.

45. Hallbook F, Wilson K, Thorndyke M, Olinski RP. Formation and evolution of the chordate neurotrophin and TrkB receptor genes. *Brain Behav Evol*. 2006;68(3):133–144.

46. Huang EJ, Reichardt LF. Trk receptors: roles in neuronal signal transduction. *Annu Rev Biochem*. 2003;72:609–642.

47. Nico B, Mangieri D, Benagiano V, Crivellato E, Ribatti D. Nerve growth factor as an angiogenic factor. *Microvasc Res*. 2008;75(2):135–141.

48. Kraemer R, Hempstead BL. Neurotrophins: novel mediators of angiogenesis. *Front Biosci*. 2003;8:s1181–s1186.

49. Hood JD, Cheshire DA. Role of integrins in cell invasion and migration. *Nat Rev Cancer*. 2002;2(2):91–100.

50. Sun L, Hui AM, Su Q, et al. Neuronal and glioma-derived stem cell factor induces angiogenesis within the brain. *Cancer Cell*. 2006;9(4):287–300.

51. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. *Science*. 1983;219(4587):983–985.

52. Ferrara N, Henzel WJ. Pituicyte follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. *Biochem Biophys Res Commun*. 1989;161(2):851–858.

53. Connolly DT, Olander JV, Heuvelman D, et al. Human vascular permeability factor. Isolation from U937 cells. *J Biol Chem*. 1989;264(50):989–991.

54. Houck KA, Ferrara N, Winer J, Cachianes G, Li B, Leung DW. The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. *Mol Endocrinol*. 1991;5(12):1806–1814.

55. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. *Science*. 1989;246(4935):1306–1309.

56. de Vries C, Escobedo JA, Ueno H, Houck K, Ferrara N, Williams LT. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. *Science*. 1992;255(5047):989–991.

57. Shibuya M, Yamaguchi S, Yamane A, et al. Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family. *Oncogene*. 1990;5(4):519–524.

58. Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L. VEGF receptor signalling – in control of vascular function. *Nat Rev Mol Cell Biol*. 2006;7(5):359–371.

59. Terman BI, Dougher-Vernazen M, Carrion ME, et al. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. *Biochem Biophys Res Commun*. 1992;187(3):1579–1586.

60. Takahashi M, Matsuai A, Inao M, Mochida S, Fujiwara K, ERK/MAPK-dependent PI3K/Akt phosphorylation through VEGFR-1 after VEGF stimulation in activated hepatic stellate cells. *Hepatol Res*. 2003;26(3):232–236.

61. Takahashi T, Shibuya M. The 230 kDa mature form of KDR/Flik-1 (VEGF receptor-2) activates the PLC-gamma pathway and partially induces mitotic signals in NIH3T3 fibroblasts. *Oncogene*. 1997;14(17):2079–2089.

62. Jones MK, Itani RM, Wang H, et al. Activation of VEGF and Ras genes in gastric mucosa during angiogenic response to ethanol injury. *Am J Physiol*. 1999;276(6 Pt 1):G1345–G1355.

63. Gerber HP, McMurtry A, Kowsalji J, et al. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/Akt signal transduction pathway. Requirement for Flik-1/KDR activation. *J Biol Chem*. 1998;273(46):30336–30343.

64. Gille H, Kowsalji J, Li B, et al. Analysis of biological effects and signaling properties of Flik-1 (VEGFR-1) and KDR (VEGFR-2). A reassessment using novel receptor-specific vascular endothelial growth factor mutants. *J Biol Chem*. 2001;276(5):3222–3230.

65. Hellstrom M, PngLK, Hoffman H, et al. Dll4 signalling through Notch regulates formation of tip cells during angiogenesis. *Nature*. 2007;445(7129):776–780.

66. Ridgway J, Zhang G, Wu Y, et al. Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis. *Nature*. 2006;444(7122):1083–1087.

67. Noquera-Troise I, Daly C, Papadopoulos NJ, et al. Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. *Nature*. 2006;444(7122):1032–1037.

68. Boulton ME, Cai J, Grant MB. gamma-Secretase: a multifaceted regulator of angiogenesis. *J Cell Mol Med*. 2008;12(3):781–795.

69. Selkoe D, Kowan R. Notch and Presenilin: regulated intramembrane proteolysis links development and degeneration. *Ann Rev Neurosci*. 2003;26:565–597.
70. Boulton ME, Cai J, Grant MB, Zhang Y. Gamma-secretase regulates VEGFR-1 signalling in vascular endothelium and RPE. *Adv Exp Med Biol.* 2008;613:313–319.

71. Hirano H, Lopes MB, Laws ER Jr, et al. Insulin-like growth factor-I content and pattern of expression correlates with histopathologic grade in diffusely infiltrating astrocytomas. *Neuro Oncol.* 1999; 1(2):109–119.

72. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. *Nat Med.* 2005; 9(6):660–676.

73. Matsumoto T, Claesson-Welsh L. VEGF receptor signal transduction. *Sci STKE.* 2001; 2001(112):RE21.

74. Benjamin LE, Golijanin D, Itin A, Pode D, Keshet E. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. *J Clin Invest.* 1999; 103(2):159–165.

75. Ku DD, Zaleski JK, Liu S, Brock TA. Vascular endothelial growth factor induces EDRF-dependent relaxation in coronary arteries. *Am J Physiol.* 1993;265(2 Pt 2):H586–H592.

76. Clauss M, Gerlach M, Gerlach H, et al. Vascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration. *J Exp Med.* 1999;180(6):1535–1545.

77. Gabrilovich DI, Chen HL, Girgis KR, et al. Production of vascular endothelial growth factor-1 in glioblastoma prolongs survival but results in increased vascular permeability. *Nat Med.* 1996;2(10):1096–1103.

78. Carmeliet P. Blood vessels and nerves: common signals, pathways and diseases. *Nat Genet.* 2003;4(9):710–720.

79. Calabrese C, Poppleton H, Kocak M, et al. A perivascular niche for brain tumor stem cells. *Cancer Cell.* 2007;11(1):69–82.

80. Rubenstein JL, Kim J, Ozawa T, et al. Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. *Neoplasia.* 2000;2(4):306–314.

81. Kunkel P, Ulbricht U, Bohlen P, et al. Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2. *Cancer Res.* 2001;61(18):6624–6628.

82. Presta LG, Chen H, O'Connor SJ, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for therapy of solid tumors and other disorders. *Cancer Res.* 1997;57(20):4593–4599.

83. Lin YS, Nguyen C, Mendoza JL, et al. Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor. *J Pharmacol Exp Ther.* 1999;288(1):371–378.

84. Ignoffo RJ. Overview of bevacizumab: a new cancer therapeutic strategy targeting vascular endothelial growth factor. *Am J Health Syst Pharm.* 2004;61(21 Suppl 5):S21–S26.

85. Cabebe E, Wakelee H. Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors. *Curr Treat Options Oncol.* 2007;8(1):15–27.

86. Escudier B, Cosaert J, Pisa P. Bevacizumab: direct anti-VEGF therapy in renal cell carcinoma. *Expert Rev Anticancer Ther.* 2008;8(10):1545–1557.

87. Gianantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. *J Clin Oncol.* 2007;25(12):1539–1544.

88. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. *N Engl J Med.* 2004;350(23):2335–2342.

89. Kabbinavar FF, Hambleton J, Mass RD, Hurwitz HI, Bergsland E, Sarkar S. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. *J Clin Oncol.* 2005;23(16):3706–3712.

90. Miller KD. E2100: a phase III trial of paclitaxel versus paclitaxel/bevacizumab for metastatic breast cancer. *Clin Breast Cancer.* 2003;3(6):421–422.

91. Ali SA, McHayle WM, Ahmad A, et al. Bevacizumab and irinotecan therapy in glioblastoma multiforme: a series of 13 cases. *J Neurosurg.* 2009;109(2):268–272.

92. Nayar A, Kelly P, Gofinios J, et al. Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival. *J Neurosurg.* 2009;110(1):173–180.

93. Poulson HS, Grunnet K, Sorensen M, et al. Bevacizumab plus irinotecan in the treatment patients with progressive recurrent malignant brain tumours. *Acta Oncol.* 2009;48(1):52–58.

94. Zuniga RM, Torcuator R, Jain R, et al. Efficacy, safety and patterns of response in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan. *J Neurooncol.* 2009;91(3):329–336.

95. Kang TY, Jin T, Elenizano H, Peerboom D. Irinotecan and bevacizumab in progressive primary brain tumors, an evaluation of efficacy and safety. *J Neurooncol.* 2008;89(1):113–118.

96. Nghiemphu PL, Liu W, Lee Y, et al. Bevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experience. *Neurology.* 2009;72(4):1217–1222.

97. Norden AD, Young GS, Setayesh K, et al. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. *Neurology.* 2008 Mar 4;70(10):779–787.

98. Vredenburgh JJ, Desjardins A, Herndon JD 2nd, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. *J Clin Oncol.* 2007;25(30):4722–4729.

99. Ballman KV, Buckner JC, Brown PD, et al. The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme. *Neuro Oncol.* 2007;9(1):29–38.

100. Lamborn KR, Yung WK, Chang SM, et al. Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. *Neuro Oncol.* 2008 Apr;10(2):162–170.

101. Friedman HS, Prados MD, Ween PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. *J Clin Oncol.* 2009;27(28):4733–4740.

102. Kreisl TN, Kim L, Moore K, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. *J Clin Oncol.* 2009;27(5):740–745.

103. Batchelor TT, Gilbert MR, Supko JG, et al. Phase 2 study of weekly irinotecan in adults with recurrent malignant glioma: final report of NABTT 97-11. *Neuro Oncol.* 2004;6(1):21–27.

104. Prados MD, Lamborn K, Yung WK, et al. A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. *Neuro Oncol.* 2006;8(2):189–193.

105. Mohile NAAL, Lymberis SC, Karimi S, Hou BL, Gutin PH. A pilot study of bevacizumab and stereotactic intensity modulated re-irradiation for recurrent high grade gliomas. *ASCO Meeting Abstracts.* 2007;25(18 Suppl):2028.

106. Nicholas MK LR, Arzbacheer J, Paleologos N, Krouwer H, Malkin M, et al. Bevacizumab in combination with temozolomide in the adjuvant treatment of newly diagnosed glioblastoma multiforme: Preliminary results of a phase II study. *ASCO Meeting Abstracts.* 2009;25(15s):2016.

107. Lai A, Filka E, McGibbon B, et al. Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: interim analysis of safety and tolerability. *Int J Radiat Oncol Biol Phys.* 2008;71(5):1372–1380.

108. Nagy MS, Arzbacheer J, Paleologos N, et al. Feasibility of using bevacizumab with radiation therapy and temozolomide in newly diagnosed high-grade glioma. *Int J Radiat Oncol Biol Phys.* 2008;72(2):383–389.

109. Gruber ML, Raza S, et al. Bevacizumab in combination with radiotherapy plus concomitant and adjuvant temozolomide for newly diagnosed glioblastoma: Update progression-free survival, overall survival, and toxicity. *ASCO Meeting Abstracts.* 2009;27(15s):2017.
110. Marc R Gilbert, et al. RTOG. Temozolomide and Radiation Therapy with or without Bevacizumab in treating patients with newly diagnosed glioblastoma or Gliosarcoma. http://clinicaltrials.gov/ct2/show/NCT00884741.

111. Hoffmann-LaRoche CT. A study of Avastin in combination with Temozolomide and Radiotherapy in patients with newly diagnosed glioblastoma. http://clinicaltrials.gov/ct2/show/NCT00943826.

112. Ananthnarayan S, Bahng J, Roring J, et al. Time course of imaging changes of GBM during extended bevacizumab treatment. J Neurooncol. 2008 Jul;88(3):339–347.

113. Wefel JSCT, Zazzali J, Friedman HS; for the BI. Neurocognitive function in patients with glioblastoma multiforme in first or second relapse treated with bevacizumab in the BRAIN study. ASCO Meeting Abstracts. 2009;27(15S):20256.

114. Pope WB, Kim HJ, Huo J, et al. Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment. Radiology. 2009;252(1):182–189.

115. Desjardins ABD, Herndon JE II, Reardon DA, Quinn JA, Rich JN, et al. Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) evaluation in glioblastoma (GBM) patients treated with bevacizumab (BEV) and irinotecan (CPT-11). ASCO Meeting Abstracts. 2007; 25(18 Suppl):2029.

116. Paldino M DA, Friedman HS, Vredenburgh JJ, Barboriak DP. Prognostic significance of early changes in the apparent diffusion coefficient that occurs after treatment of patients with glioblastoma multiforme with bevacizumab. ASCO Meeting Abstracts. 2009;27(15S):2058.

117. Lucio-Eterovic AK, Piao Y, de Groot JF. Mediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapy. Clin Cancer Res. 2009;15(14):4589–4599.

118. Iwamoto FM, Abrey LE, Beal K, et al. Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma. Neurology. 2009;73(15):1200–1206.

119. Quant EC, Norden AD, Drappatz J, et al. Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab. Neuro Oncol. 2009;11(5):550–555.

120. Potthast LCS, Pan E, Yu D, Zhu W, Brem S. The infiltrative, diffuse pattern of recurrence in patients with malignant gliomas treated with bevacizumab. ASCO Meeting Abstracts. 2009;27(15S):2057.